Raimundo, PedroMiranda, ARibeiro, JMansinho, Kamal2017-06-272017-06-272010-071646-0758PURE: 500590PURE UUID: 5cbcde75-2ae0-4c5a-bae9-0ccdac0c97f3researchoutputwizard: 14833PubMed: 20687996WOS: 000282525800014Scopus: 78349249088http://hdl.handle.net/10362/21735The increased cardiovascular risk has been implicated in both HIV infection and antirretroviral therapy. The endothelial dysfunction triggered by the infection and the metabolic abnormalities associated with therapy predispose to premature atherosclerosis. The recognition of the increased cardiovascular risk in these patients will allow more appropriate prevention strategies, as well as therapy optimization with lipid-lowering agents and antirretroviral therapy modification.7242630por:IMMUNODEFICIENCY-VIRUS-INFECTIONPROTEASE INHIBITOR THERAPYTREATMENT PANEL-IIIANTIRETROVIRAL THERAPYMETABOLIC SYNDROMEINSULIN-RESISTANCEDYSLIPIDEMIAMANAGEMENTEFAVIRENZADULTSSDG 3 - Good Health and Well-beingjournal article